Dr Patel on the Potential for Adjuvant Immunotherapy in CSCC
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Radioligand Therapies and Emerging Targets Drive Innovation in Prostate Cancer Management
Time-Limited Zanubrutinib/Rituximab Yields Durable Remissions in Treatment-Naive CLL
TAR-200 Is Poised to Become a Targeted, Tolerable Addition to BCG-Unresponsive NMIBC Treatment Arsenal
Efineptakin Alfa Represents Potentially Effective Option in Kaposi Sarcoma
2 Commerce Drive
Cranbury, NJ 08512